Arhgef38, Rho guanine nucleotide exchange factor 38, is related to tumor cell polarization. It may participate in the tumor cell metastasis pathway. It has potential significance in understanding genetic-epigenetic interactions and is associated with various biological processes and disease conditions [1,4].

In prostate cancer, Arhgef38 is significantly up-regulated and its expression is higher in tumors with a higher Gleason score. Functional experiments showed that silencing Arhgef38 suppressed the proliferation, migration, and invasiveness of prostate cancer cells, indicating it may serve as an oncogene in prostate cancer [1,3].

In breast cancer, a low-frequency missense variant rs61751053 in ARHGEF38 is associated with overall breast cancer in women of African ancestry [2].

In addition, in the context of infective endocarditis, the type IV collagen-Cnm-ARHGEF38 pathway may play a crucial role as knockdown of ARHGEF38 strongly reduced human umbilical vein endothelial cell invasion by Cnm-positive Streptococcus mutans [5].

In summary, Arhgef38 is involved in tumor-related processes such as cell metastasis, proliferation, migration, and invasion, especially in prostate cancer. Its role in breast cancer and infective endocarditis also indicates its importance in different disease areas. Studies on Arhgef38 contribute to understanding the mechanisms of these diseases and may provide potential targets for treatment [1,2,3,5].